Organization
Mercy Medical Center
2 clinical trials
2 abstracts
Abstract
Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.Org: Advanced Molecular Imaging and Therapy, Hoag Family Cancer Institute and University of Southern California, Hunstman Cancer Hospital, University of Utah Health, University of Kentucky, Markey Cancer Center, Department of Medical Oncology, Mercy Medical Center,
Clinical trial
Phase II Randomized Study: Cytoreductive Surgery (CRS) With/Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Adjuvant Chemotherapy as Initial Treatment of Ovarian, Fallopian Tube, & Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2027-08-01
Clinical trial
Clinical Trial to Define the Effect of Perioperative H. Pylori Eradication With Antibiotic Treatment on Long Term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Abstract
ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Initial safety analysis.Org: Advanced Molecular Imaging and Therapy, Hoag Family Cancer Institute and University of Southern California, MD Anderson Cancer Center, Moffitt Cancer Center and Research Institute, Nebraska Cancer Specialists,